The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer
Open accessAbstract
Tamoxifen-based endocrine therapy remains a major adjuvant therapy for estrogen receptor (ER)-positive breast cancer (BC). However, many patients develop tamoxifen resistance, which results in recurrence and poor prognosis. Herein, we show that fatty acid oxidation (FAO) was activated in tamoxifen-resistant (TamR) ER-positive BC cells by performing bioinformatic and functional studies. We also reveal that CPT1A, the rate-limiting enzyme of FAO, was significantly overexpressed and that its enzymatic activity was enhanced in TamR cells. Mechanistically, the transcription factor c-Jun was activated by JNK kinase-mediated phosphorylation. Activated c-Jun bound to the TRE motif in the CPT1A promoter to drive CPT1A transcription and recruited CBP/P300 to chromatin, catalysing histone H3K27 acetylation to increase chromatin accessibility, which ensured more effective transcription of CPT1A and an increase in the FAO rate, eliminating the cytotoxic effects of tamoxifen in ER-positive BC cells. Pharmacologically, inhibiting CPT1A enzymatic activity with the CPT1 inhibitor etomoxir or blocking c-Jun phosphorylation with a JNK inhibitor restored the tamoxifen sensitivity of TamR cells. Clinically, high levels of phosphorylated c-Jun and CPT1A were observed in ER-positive BC tissues in patients with recurrence after tamoxifen therapy and were associated with poor survival. These results indicate that the assessment and targeting of the JNK/c-Jun-CPT1A-FAO axis will provide promising insights for clinical management, increased tamoxifen responses and improved outcomes for ER-positive BC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In this system, HA and 4-OH-TAM mediated the nanomicelle targeting and enrichment in TAM-resistant breast cancer by the overexpression of ER and cluster of differentiation (CD44) receptors28,29.”
From Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer (2026) · cites this paper as [28]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Han, J., Qu, H., Han, M., Ding, Y., Xie, M., Hu, J., Chen, Y., & Dong, H. (2020) · Oncogene · doi:10.1038/s41388-020-01574-8 · Cited by 92 · cited 17×
“The precipitation was collected for protein quanti fi cation, and the supernatant was collected for ATP detection.”
InfluentialRetractedSiegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
Metascape provides a biologist-oriented resource for the analysis of systems-level datasets
Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., Benner, C., & Chanda, S. K. (2019) · Nature Communications · doi:10.1038/s41467-019-09234-6 · Cited by 14,611
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887 · cited 1×
“Tumour cell reprogramming of cellular metabolism supports the molecular interpretation of the malignant biological behaviour of cancer [7].”
Breast cancer statistics, 2019
DeSantis, C. E., Ma, J., Gaudet, M. M., Newman, L. A., Miller, K. D., Goding Sauer, A., Jemal, A., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21583 · Cited by 3,114 · cited 1×
“Estrogen receptor (ER)-positive BC is the most common BC subtype, accounting for approximately 80% of all BC cases [2].”
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251194298 · Cited by 2,558 · cited 1×
“All the research was carried out in accordance with the provisions of the Helsinki Declaration of 1975.”
AP-1: a double-edged sword in tumorigenesis
Eferl, R., & Wagner, E. F. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1209 · Cited by 2,242 · cited 1×
“In addition, the c-Jun S63A construct induced only minor effects on the promoter activity of CPT1A compared to profound effects mediated by the c-Jun wild-type construct (Fig.”
Loibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Cancer metabolism: fatty acid oxidation in the limelight
Carracedo, A., Cantley, L. C., & Pandolfi, P. P. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3483 · Cited by 1,324
ChEA3: transcription factor enrichment analysis by orthogonal omics integration
Keenan, A. B., Torre, D., Lachmann, A., Leong, A. K., Wojciechowicz, M. L., Utti, V., Jagodnik, K. M., Kropiwnicki, E., Wang, Z., & Ma’ayan, A. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz446 · Cited by 1,136
Cited by
Chromatin accessibility: biological functions, molecular mechanisms and therapeutic application
Chen, Y., Liang, R., Li, Y., Jiang, L., Ma, D., Luo, Q., & Song, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02030-9 · Cited by 221
Wan, M., Pan, S., Shan, B., Diao, H., Jin, H., Wang, Z., Wang, W., Han, S., Liu, W., He, J., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02258-1 · Cited by 110
“Mechanistically, c-Jun recruits CBP/P300 to the CPT1A promoter, initiating CPT1A transcription in ER-positive BC cells [284].”
Post-translational modifications in drug resistance
Miao, C., Huang, Y., Zhang, C., Wang, X., Wang, B., Zhou, X., Song, Y., Wu, P., Chen, Z., & Feng, Y. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101173 · Cited by 77
The role and mechanism of fatty acid oxidation in cancer drug resistance
Lei, Y., Cai, S., Zhang, J., Ding, S., Zhang, Z.-H., Zhang, C., Dai, D., & Li, Y. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02554-1 · Cited by 59
“Inhibition of FAO can restore the sensitivity of resistant cells to tamoxifen [144].”
Lipid metabolism involved in progression and drug resistance of breast cancer
Fu, W., Sun, A., & Dai, H. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101376 · Cited by 35
Metadata
- Authors
- Jiang, C., Zhu, Y., Chen, H., Lin, J., Xie, R., Li, W., Xue, J., Chen, L., Chen, X., & Xu, S.
- Affiliations
- Union Hospital (CN)
- Fujian Medical University (CN)
- Corresponding author
- Chen, Xiangjin
- Xu, Sunwang
- Venue
- Cell Death & Disease
- Published
- 2023-10-06
- Volume
- 14
- Issue
- 10
- Pages
- 653-653
- ISSN
- 2041-4889 (ISSN-L)
- PMC
- PMC10558541
- OpenAlex
- W4387399646
- Cited by
- 36
- References
- 66
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 10
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cell Death and Disease (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82103549, 82273367)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- tamoxifen resistance, estrogen receptor-positive breast cancer, fatty acid oxidation, c-Jun, JNK phosphorylation, CPT1A, endoplasmic reticulum stress, CBP/p300, histone H3K27 acetylation, chromatin accessibility, etomoxir, endocrine therapy resistance, tumor recurrence
- MeSH terms
- Breast Neoplasms, Chromatin, Fatty Acids, Female, Humans, Receptors, Estrogen, Tamoxifen, Gene Expression Regulation, Neoplastic, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer. https://app.cochat.ai/papers/10.1038/s41419-023-06181-5
- The paper
- Jiang, C., Zhu, Y., Chen, H., Lin, J., Xie, R., Li, W., Xue, J., Chen, L., Chen, X., & Xu, S. (2023). Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer. Cell Death & Disease. https://doi.org/10.1038/s41419-023-06181-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.